[go: up one dir, main page]

PE20170429A1 - Vacuna en vector recombinante de adenovirus aviar serotipo 9 - Google Patents

Vacuna en vector recombinante de adenovirus aviar serotipo 9

Info

Publication number
PE20170429A1
PE20170429A1 PE2017000180A PE2017000180A PE20170429A1 PE 20170429 A1 PE20170429 A1 PE 20170429A1 PE 2017000180 A PE2017000180 A PE 2017000180A PE 2017000180 A PE2017000180 A PE 2017000180A PE 20170429 A1 PE20170429 A1 PE 20170429A1
Authority
PE
Peru
Prior art keywords
vaccine
adenovirus serotype
avian adenovirus
glycoprotein
affected
Prior art date
Application number
PE2017000180A
Other languages
English (en)
Inventor
Bernardo Lozano-Dubernard
Ernesto Soto-Priante
David Sarfati-Mizrahi
Original Assignee
Grupo Ind Pecuario S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grupo Ind Pecuario S A De C V filed Critical Grupo Ind Pecuario S A De C V
Publication of PE20170429A1 publication Critical patent/PE20170429A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una vacuna recombinante que comprende un vector de adenovirus aviar serotipo 9 (FAdV-9), que comprende la secuencia de aminoacidos SEQ ID NO:1 que tiene insertada por lo menos una secuencia de nucleotidos exogena que codifica para un antigeno del grupo que comprende hemoaglutinina (HA) del virus de influenza aviar, glicoproteina B (gB) y glicoproteina D (gD) del virus de laringotraqueitis infecciosa de las aves (LTI), entre otros; y un vehiculo, adyuvante y/o excipiente farmaceuticamente aceptable. Dicha vacuna es estable cuando se produce a escala industrial y al ser administrada en combinacion con una vacuna contra la enfermedad de Marek, ambas producen una respuesta inmune adecuada que no se ve afectada por la interferencia entre ellas; asimismo, su efectividad no se ve afectada por los anticuerpos maternos
PE2017000180A 2014-08-08 2015-08-06 Vacuna en vector recombinante de adenovirus aviar serotipo 9 PE20170429A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2014/063809 WO2016020730A1 (es) 2014-08-08 2014-08-08 Vacuna en vector recombinante de adenovirus aviar serotipo 9

Publications (1)

Publication Number Publication Date
PE20170429A1 true PE20170429A1 (es) 2017-05-11

Family

ID=55263220

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017000180A PE20170429A1 (es) 2014-08-08 2015-08-06 Vacuna en vector recombinante de adenovirus aviar serotipo 9
PE2022001034A PE20221792A1 (es) 2014-08-08 2015-08-06 Vacuna en vector recombinante de adenovirus aviar serotipo 9

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2022001034A PE20221792A1 (es) 2014-08-08 2015-08-06 Vacuna en vector recombinante de adenovirus aviar serotipo 9

Country Status (14)

Country Link
US (1) US10758608B2 (es)
EP (1) EP3178938A4 (es)
JP (1) JP2017526737A (es)
KR (1) KR20170063552A (es)
CN (1) CN106661592A (es)
AR (1) AR101468A1 (es)
BR (1) BR112017002577A2 (es)
CA (1) CA2956997A1 (es)
CO (1) CO2017001614A2 (es)
EA (1) EA038951B1 (es)
MX (3) MX2017001742A (es)
PE (2) PE20170429A1 (es)
PH (1) PH12017500216B1 (es)
WO (2) WO2016020730A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107037526A (zh) 2008-08-08 2017-08-11 3M创新有限公司 具有粘弹性层的用于控制光的光导
WO2016020730A1 (es) * 2014-08-08 2016-02-11 Laboratorio Avi-Mex, S.A. De C.V. Vacuna en vector recombinante de adenovirus aviar serotipo 9
CN108126191B (zh) * 2016-12-01 2021-04-06 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN108653724B (zh) * 2017-04-01 2020-11-27 普莱柯生物工程股份有限公司 一种用于预防禽减蛋综合征的疫苗组合物、及其制备方法和应用
CN110680914B (zh) * 2019-09-23 2021-11-26 洛阳职业技术学院 一种三联灭活疫苗及其制备方法
CN111494617A (zh) * 2020-04-08 2020-08-07 扬州优邦生物药品有限公司 一种四联灭活疫苗及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103939A (en) * 1992-12-01 1996-09-12 Abic Ltd An anti-DBI vaccine in birds containing attenuated live DBI virus
US6296852B1 (en) * 1993-04-14 2001-10-02 Commonwealth Scientific And Industrial Research Organisation Recombinant avian adenovirus vector
WO1994024268A1 (en) 1993-04-14 1994-10-27 Arthur Webster Pty. Ltd. Recombinant avian adenovirus vector
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20100003279A1 (en) * 2005-12-22 2010-01-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccine for in ovo inoculation
KR20110081222A (ko) * 2008-09-26 2011-07-13 어번 유니버시티 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
CN102281896A (zh) 2008-11-19 2011-12-14 阿维-梅克斯实验室公司 重组失活病毒载体疫苗
WO2016020730A1 (es) * 2014-08-08 2016-02-11 Laboratorio Avi-Mex, S.A. De C.V. Vacuna en vector recombinante de adenovirus aviar serotipo 9
RS66242B1 (sr) * 2015-07-10 2024-12-31 Univ Guelph Vektorski sistem adenovirusa živine 9 (fadv-9) i povezani postupci

Also Published As

Publication number Publication date
WO2016020885A1 (es) 2016-02-11
AR101468A1 (es) 2016-12-21
WO2016020730A1 (es) 2016-02-11
MX2017001742A (es) 2017-05-15
PH12017500216A1 (en) 2017-07-03
CN106661592A (zh) 2017-05-10
EA038951B1 (ru) 2021-11-15
MX2022000718A (es) 2022-02-24
MX2022003590A (es) 2022-05-26
US10758608B2 (en) 2020-09-01
BR112017002577A2 (pt) 2018-02-27
JP2017526737A (ja) 2017-09-14
US20170232096A1 (en) 2017-08-17
PE20221792A1 (es) 2022-11-25
EA201790296A1 (ru) 2017-06-30
PH12017500216B1 (en) 2021-05-05
CA2956997A1 (en) 2016-02-11
KR20170063552A (ko) 2017-06-08
EP3178938A4 (en) 2018-03-21
EP3178938A1 (en) 2017-06-14
CO2017001614A2 (es) 2017-07-28

Similar Documents

Publication Publication Date Title
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
CO7160021A2 (es) Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares
AR110458A1 (es) Vacunas de fmdv vectorizadas con adenovirus recombinantes y usos de las mismas
MX2018015756A (es) Construcciones de virus de la enfermedad de marek recombinantes no patogenicas codificadoras de antigenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad bursal infecciosa.
MX2020003591A (es) Constructos del virus recombinante no patogenico de la enfermedad de marek que codifica multiples antigenos heterologos.
MX2015011487A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
MX363464B (es) Vacunas contra influenza h5.
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
CL2019000405A1 (es) Vacunas virales.
MX2019007924A (es) Vacunas contra la influenza.
AR109540A1 (es) Moléculas promotoras para expresar antígenos virales
DOP2014000215A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
CO2022005281A2 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
MX2022001430A (es) Formulaciones de vacuna contra chikungu?a.
AR130779A1 (es) Vacunas de combinación
AR120296A1 (es) Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso
AR113755A1 (es) Constructos de virus de la enfermedad de marek no patógenos recombinantes que codifican antígenos heterólogos múltiples
AR106463A1 (es) Vacunas de ácido nucleico para el virus varicela-zóster (vzv)
UA126846U (uk) Авівак-іеквм-2 - вакцина асоційована інактивована проти ньюкаслської хвороби, інфекційної бурсальної хвороби, інфекційного бронхіту курей та синдрому зниження несучості
MX2014014089A (es) Peptido recombinante de la porina de 42-kda, uso como antigeno vacunal y en la deteccion de anticuerpos contra histophilus somni.
EA202191862A2 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения